1. Home
  2. BELFB vs MLYS Comparison

BELFB vs MLYS Comparison

Compare BELFB & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BELFB
  • MLYS
  • Stock Information
  • Founded
  • BELFB 1949
  • MLYS 2019
  • Country
  • BELFB United States
  • MLYS United States
  • Employees
  • BELFB N/A
  • MLYS 51
  • Industry
  • BELFB
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • BELFB
  • MLYS Health Care
  • Exchange
  • BELFB Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • BELFB 865.9M
  • MLYS 1.0B
  • IPO Year
  • BELFB N/A
  • MLYS 2023
  • Fundamental
  • Price
  • BELFB $73.80
  • MLYS $15.58
  • Analyst Decision
  • BELFB Strong Buy
  • MLYS Strong Buy
  • Analyst Count
  • BELFB 3
  • MLYS 3
  • Target Price
  • BELFB $98.33
  • MLYS $33.00
  • AVG Volume (30 Days)
  • BELFB 78.9K
  • MLYS 866.7K
  • Earning Date
  • BELFB 07-23-2025
  • MLYS 05-12-2025
  • Dividend Yield
  • BELFB 0.38%
  • MLYS N/A
  • EPS Growth
  • BELFB N/A
  • MLYS N/A
  • EPS
  • BELFB 3.42
  • MLYS N/A
  • Revenue
  • BELFB $558,940,000.00
  • MLYS N/A
  • Revenue This Year
  • BELFB $18.21
  • MLYS N/A
  • Revenue Next Year
  • BELFB $7.91
  • MLYS N/A
  • P/E Ratio
  • BELFB $21.25
  • MLYS N/A
  • Revenue Growth
  • BELFB N/A
  • MLYS N/A
  • 52 Week Low
  • BELFB $58.00
  • MLYS $8.24
  • 52 Week High
  • BELFB $92.61
  • MLYS $18.38
  • Technical
  • Relative Strength Index (RSI)
  • BELFB 51.90
  • MLYS 54.41
  • Support Level
  • BELFB $71.75
  • MLYS $15.45
  • Resistance Level
  • BELFB $74.61
  • MLYS $16.11
  • Average True Range (ATR)
  • BELFB 2.66
  • MLYS 0.96
  • MACD
  • BELFB -0.25
  • MLYS -0.05
  • Stochastic Oscillator
  • BELFB 40.34
  • MLYS 51.56

About BELFB Bel Fuse Inc. Class B

Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: